Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1236 results
November 2018
-
Press Release
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
Alcon is the global leader in the highly attractive and growing $23 billion eye care devices market Market leading development capabilities and innovation investments Clearly defined near and… -
Press Release
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65… -
Press Release
Novartis rises to second place in 2018 Access to Medicine Index
Company leads the industry in access-to-medicine management thanks to long- term commitment, as well as ongoing innovation in access to healthcare Novartis moves up one position from number 3 in… -
Press Release
Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder
reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of… -
Press Release
FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation Approval… -
Press Release
Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs. endocrine therapy alone[1] CHMP opinion is… -
Ad-hoc Releases
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
Basel, November 13, 2018 - Novartis today announced that Alcon has filed an initial Form 20-F registration statement with the US Securities and Exchange Commission (SEC) in relation to the previously… -
Press Release
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker… -
Press Release
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
26 potential blockbusters in confirmatory development[1]. 13 projects in clinical development across Cell, Gene & Radioligand therapies. 60 major submissions[2] planned from 2019 to 2021… -
Press Release
Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is… -
Press Release
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2-…